Disparities in Outcomes of Hospitalizations Due to Multiple Myeloma: A Nationwide Comparison.

length of stay multiple myeloma multiple myeloma prognosis multiple myeloma treatment newest treatment for multiple myeloma temporal trends

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Oct 2023
Historique:
accepted: 12 10 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Background With the advent of novel treatments, there is a declining trend in the multiple myeloma (MM) mortality rate with an increasing hospitalization rate. However, there is limited population-based data on trends and outcomes of hospitalizations due to MM in the United States (US). Methods We analyzed the publicly available Nationwide Inpatient Sample (NIS) from 2007 to 2017 to identify MM hospitalizations. Results Hospitalizations for MM increased from 17,100 (8.71%) in 2007 to 19,490 (9.92%) in 2017. The in-hospital mortality rate declined from 8.4% in 2007 to 4.9% in 2017 (P <0.001) and discharge to facilities decreased from 20.4% in 2007 to 17.4% in 2017 (P <0.001). The odds of in-hospital mortality were higher with increasing age (odds ratio (OR): 1.46; 95% confidence interval (CI): 1.38 -1.54; P <0.0001), pneumonia (OR: 4.18; 95% CI: 3.63 - 4.81, P <0.0001), septicemia (OR: 2.50; 95% CI: 2.22 - 2.82; P <0.0001), renal failure (OR: 1.48; 95% CI: 1.34 -1.64; P <0.0001), uninsured/self-pay insurance status (OR: 2.69; 95% CI: 2.18 - 3.3; P <0.0001), rural hospital (OR: 2.26; 95% CI: 1.88 -2.72; P<0.0001), and urban-non-teaching hospitals (OR: 1.38; 95% CI: 1.23 - 1.56; P <0.0001). Also, increasing age (OR: 1.14; 95% CI: 1.11-1.18, P <0.0001), Black race (OR: 1.12; 95% CI: 1.02-1.23, P <0.0001), and multiple comorbidities were associated with higher disability. Conclusion Hospitalizations for MM continued to increase, whereas in-hospital mortality continued to decrease. Advanced age, sepsis, pneumonia, and renal failure were associated with higher odds of mortality in MM patients.

Identifiants

pubmed: 38022254
doi: 10.7759/cureus.47319
pmc: PMC10656933
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e47319

Informations de copyright

Copyright © 2023, Khadka et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Blood Adv. 2017 Jan 4;1(4):282-287
pubmed: 29296944
PLoS One. 2019 Feb 13;14(2):e0211927
pubmed: 30759167
Blood. 2013 Apr 18;121(16):3062-4
pubmed: 23599258
Leuk Lymphoma. 2015;56(9):2643-9
pubmed: 25651424
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):541-51
pubmed: 23810244
Nat Rev Cancer. 2017 Aug 24;17(9):543-556
pubmed: 28835722
Eur J Haematol. 2018 Apr 20;:
pubmed: 29676004
Semin Oncol. 1986 Sep;13(3):282-90
pubmed: 3532328
Best Pract Res Clin Haematol. 2005;18(4):635-52
pubmed: 16026742
Cancer Epidemiol. 2018 Apr;53:105-110
pubmed: 29414629
Oncol Ther. 2021 Jun;9(1):195-212
pubmed: 33728584
Front Oncol. 2020 Jan 24;9:1513
pubmed: 32039008
Clin Med Circ Respirat Pulm Med. 2008 Apr 18;2:19-25
pubmed: 21157518
Leukemia. 2020 Feb;34(2):604-612
pubmed: 31611625
Eur J Haematol. 2005 Nov;75(5):370-5
pubmed: 16191085
Leukemia. 2017 Sep;31(9):1915-1921
pubmed: 28008176
Eur J Cancer. 2011 Jul;47(11):1606-15
pubmed: 21354783
Blood Cancer J. 2018 Nov 9;8(11):109
pubmed: 30413684
Am J Hematol. 2017 Sep;92(9):915-923
pubmed: 28543165
Oncotarget. 2017 Jul 11;8(28):46593-46600
pubmed: 28423741
Int J Lab Hematol. 2009 Aug;31(4):375-83
pubmed: 19486365
Psychooncology. 2020 Oct;29(10):1587-1594
pubmed: 32658348
Br J Cancer. 1998;77(3):485-91
pubmed: 9472648
Blood. 2010 Dec 16;116(25):5501-6
pubmed: 20823456
J Clin Oncol. 2007 May 20;25(15):1993-9
pubmed: 17420512
Int J Cancer. 2020 Dec 1;147(11):3102-3109
pubmed: 32506433
Eur J Cancer. 2010 Jan;46(1):160-9
pubmed: 19682891
Clin Infect Dis. 2009 Oct 15;49(8):1211-25
pubmed: 19769539
Blood Cancer J. 2018 Mar 8;8(3):30
pubmed: 29520024
J Clin Oncol. 2014 Aug 20;32(24):2531-40
pubmed: 25071143
Mayo Clin Proc. 2010 Mar;85(3):225-30
pubmed: 20194150
J Clin Oncol. 2010 Feb 10;28(5):830-4
pubmed: 20038719
Mayo Clin Proc. 2016 Jan;91(1):101-19
pubmed: 26763514
PLoS One. 2018 May 1;13(5):e0196596
pubmed: 29715281
Med Sci (Basel). 2021 Jan 20;9(1):
pubmed: 33498356

Auteurs

Sushmita Khadka (S)

Internal Medicine, Guthrie Robert Packer Hospital, Sayre, USA.

Swetha Balaji (S)

Medicine, Scripps Clinic John R. Anderson V Medical Pavilion, San Diego, USA.

Japjeet Kaur (J)

Medicine, Sub-divisional Civil Hospital, Ajnala, IND.

Dhanshree Solanki (D)

Hospital Administration, Rutgers University, New Brunswick, USA.

Mariia Kasianchyk (M)

Medicine, Vinnytsia National Medical University, Vinnytsia, UKR.

Humayra Chowdhury (H)

Medicine, Mount Sinai Health System, New York, USA.

Ishani Patel (I)

Medicine, Houston Medical Center, Warner Robins, USA.

Muhammad Qasim (M)

Internal Medicine, Hospital Corporation of America (HCA) Healthcare/University of South Florida (USF) Morsani College of Medicine Graduate Medical Education (GME) Oak Hill Hospital, Brooksville, USA.

Maheshkumar Desai (M)

Internal Medicine, Hamilton Medical Center, Medical College of Georgia/Augusta University, Dalton, USA.

Prakash Maiyani (P)

Internal Medicine, Gold Coast University Hospital, Southport, AUS.

Dharmeshkumar V Moradiya (DV)

Internal Medicine, St. John of God Murdoch Hospital, Murdoch, AUS.

Darshan Lal (D)

Hospital Medicine, Geisinger Commonwealth School of Medicine, Scranton, USA.

Achint A Patel (AA)

Internal Medicine, Hospital Corporation of America (HCA) Healthcare/University of South Florida (USF) Morsani College of Medicine Graduate Medical Education (GME) Oak Hill Hospital, Brooksville, USA.

Manidhar Lekkala (M)

Oncology, University of Kansas, Kansas City, USA.

Classifications MeSH